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Abstract
Background: The purpose of the Finnish Cardiovascular Study (FINCAVAS) is to construct a risk
profile – using genetic, haemodynamic and electrocardiographic (ECG) markers – of individuals at
high risk of cardiovascular diseases, events and deaths.
Methods and design: All patients scheduled for an exercise stress test at Tampere University
Hospital and willing to participate have been and will be recruited between October 2001 and
December 2007. The final number of participants is estimated to reach 5,000. Technically
successful data on exercise tests using a bicycle ergometer have been collected of 2,212 patients
(1,400 men and 812 women) by the end of 2004. In addition to repeated measurement of heart
rate and blood pressure, digital high-resolution ECG at 500 Hz is recorded continuously during the
entire exercise test, including the resting and recovery phases. About 20% of the patients are
examined with coronary angiography. Genetic variations known or suspected to alter
cardiovascular function or pathophysiology are analysed to elucidate the effects and interactions of
these candidate genes, exercise and commonly used cardiovascular medications.
Discussion: FINCAVAS compiles an extensive set of data on patient history, genetic variation,
cardiovascular parameters, ECG markers as well as follow-up data on clinical events,
hospitalisations and deaths. The data enables the development of new diagnostic and prognostic
tools as well as assessments of the importance of existing markers.
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Background
Coronary heart disease (CHD) is the leading cause of
morbidity and mortality in industrial countries. The exer-
cise stress test is commonly used for diagnosing CHD. The
first and most widely applied electrocardiogram (ECG)
marker used to indicate ischemia during exercise is
depression of the ST segment [1], but several other param-
eters have been introduced to complement the informa-
tion received. Recently, some of these ECG markers have
also been proposed to serve as prognostic means for pre-
dicting the clinical course of CHD [2,3]. Moreover, exer-
cise capacity as well as the levels of and changes in blood
pressure and heart rate (HR) during the exercise test have
been suggested to predict the incidence of cardiac events
and deaths [2,4-10]. However, the results so far are not
conclusive, but rather they justify further study and
research to find novel exercise test parameters for both
diagnostic and prognostic purposes.
Genetic variation has been shown to affect the cardiac ion
channels [11,12], the sympathetic nervous system
[13,14], function of arteries and veins [15,16], regulation
of blood pressure [17,18] as well as the cardiac muscle
and contractility [19]. Consequently, hereditary differ-
ences probably explain part of the inter-individual varia-
tion in cardiovascular responses during short- and long-
term physical exercise [20]. However, few large and sys-
tematic studies have been performed on the interaction of
genes with physiological and pathophysiological cardio-
vascular responses during exercise [21]. Heavy exercise
also induces pathological cardiac disorders, such as
arrhythmia, in susceptible persons [22,23]; the possible
underlying hereditary factors are poorly known. Further-
more, to our knowledge, no studies have been published
on the interactions between genes and exercise regarding
cardiovascular mortality.
The effects of many drugs commonly used for the treat-
ment of hypertension, CHD and other cardiovascular dis-
orders vary widely from one person to another. Part of this
variation has been attributed to genetic polymorphisms in
factors contributing either to pharmacokinetics or phar-
macodynamics – i.e., to pharmacogenetics [24-26]. Since
a majority of patients with cardiovascular illnesses use
one or several types of these drugs, we hypothesise that
exercise and the polymorphisms with pharmacogenetic
influence might also have interactions affecting the phys-
iological parameters measured during a clinical exercise
test.
The Finnish Cardiovascular Study (FINCAVAS) was
designed and is being conducted to find exercise test
markers predicting future cardiovascular events and
deaths. Many of the present patients undergo coronary
angiography, and the database gives grounds for improv-
ing the diagnostic and prognostic accuracy of the exercise
test by determining associations between ECG, haemody-
namic parameters and angiographic findings. Moreover,
we aim to elucidate extensively the effects and interactions
of exercise, commonly used cardiovascular medications
and a variety of candidate genes in people without cardiac
diseases as well as in patients with CHD. As a corollary to
these, the purpose of FINCAVAS is to construct a risk pro-
file to identify individuals at a high or low risk of cardio-
vascular diseases and events.
Methods and design
Study cohort
The participant pool consists of patients who undergo
exercise stress tests at Tampere University Hospital. All the
consecutive patients coming in for an exercise stress test
and willing to participate in the study have been and will
be recruited between October 2001 and December 2007.
Our goal is to recruit roughly 5,000 patients. Currently,
the research group is actively analysing the data on the
2,212 patients (1,400 men and 812 women) recruited by
the end of 2004. The study protocol was approved by the
Ethical Committee of the Hospital District of Pirkanmaa,
Finland, and all patients have given informed consent
prior to the interview and measurements as stipulated in
the Declaration of Helsinki.
In addition, roughly one thousand patients scheduled for
spiroergometer testing (SensorMedics VMax29c, VIASYS
Healthcare Inc., Yorba Linda, CA, USA) with pre- and
post-test spirometry will be recruited between December
2005 and the end of 2007.
No specific sample size calculations were made prior to
study initiation. In general terms, if we want to find a 10%
difference in the prevalence of certain genotypes with a
significance level of p < 0.05 and to reach an 80% ability
to find significant differences between the groups, we
need hundreds of patients. Since the study population is
often divided into subgroups based on, for example, age,
sex and medication, the size of the cohort should prefera-
bly be at least one thousand.
Study flow
After an informed consent has been signed, the medical
history of each patient is gathered with a computer-based
questionnaire form [27]. Thereafter, the exercise test is
performed. Blood samples are drawn for DNA analyses.
Some of the patients are examined with coronary angiog-
raphy either before or after the exercise test.
Exercise test protocol
Prior to the exercise stress test, the subject lie down in
supine position for 10 minutes, and the resting ECG is
digitally recorded. The exercise test is performed using aBMC Cardiovascular Disorders 2006, 6:9 http://www.biomedcentral.com/1471-2261/6/9
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bicycle ergometer with electrical brakes. The lead system
used is the Mason-Likar modification of the standard 12-
lead system [28]. The initial workload varies from 20 W to
30 W, and the load is increased stepwise by 10–30 W every
minute. During the test, HR is continuously registered
with ECG, while the systolic (SAP) and diastolic (DAP)
arterial pressures are measured with a brachial cuff every
two minutes. Breathing frequency is measured and the
patient is asked about the perceived exertion level every
two minutes using Borg's scale with 15 categories [29].
Most of the exercise tests are sign- and symptom-limited
maximal tests using the recommended criteria for termi-
nation, but some of the tests for evaluating the status after
a myocardial infarction (MI) have an HR upper limit of
120–130 bpm. The recovery phase after the exercise is at
least five minutes.
Laboratory analysis and DNA extraction
FINCAVAS has access to the laboratory tests performed on
the study patients at Tampere University Hospital
between October 1998 and the end of the study. Plasma
triglycerides, total and high-density lipoprotein (HDL)
cholesterol as well as sensitive C-reactive protein (CRP)
concentrations are analysed by a Cobas Integra 700 auto-
matic analyser with reagents and calibrators recom-
mended by the manufacturer (Hoffmann-La Roche Ltd.,
Basel, Switzerland). Low-density lipoprotein (LDL) con-
centration is calculated using Friedewald's formula [30]. A
typical detection limit for CRP is 0.25 mg/l [31]. Genomic
Data sources utilised in the present study Figure 1
Data sources utilised in the present study. CHD, coronary heart disease; HR, heart rate; BP, blood pressure; MET, metabolic 
equivalent; ECG, electrocardiogram; TUH, Tampere University Hospital.
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DNA is extracted from peripheral blood leukocytes using
a commercially available kit and Qiagen BioRobot M48
Workstation according to the manufacturer's instructions
(Qiagen Inc., Hilden, Germany).
Polymorphisms, genotyping and the selection of candidate 
genes
One of the central objectives of FINCAVAS is to examine
the effects of polymorphisms known or suspected to alter
the development of atherosclerosis, cardiovascular func-
tion, pathophysiology or related pharmacogenetics.
Moreover, we aim to find new polymorphisms affecting
these processes. In the first of our two genotyping strate-
gies, the genes found to be expressed in the arterial wall –
thus possibly directly affecting the development of athero-
sclerosis – are selected for the detailed genotype-haplo-
type analysis. The selection is based on the results of
another ongoing project in which the expression of the
entire genome, roughly 30 000 genes, is scanned from 30
freshly collected arterial tissue samples with morphomet-
rically and immunohistochemically verified atheroscle-
rotic lesions.
The expression analysis is performed using Illumina Bea-
dArray™ technology (Illumina, Inc, San Diego, CA, USA).
After selecting the genes statistically most significantly
expressed in the arterial wall, we design an Illumina cus-
tom panel for up to 1536 markers for single nucleotide
polymorphisms of the genes chosen. The advantage of
this strategy is the low price per sample, which enables us
to analyse all the participants of FINCAVAS. As the price
of genotyping steadily decreases, we are technically
equipped to perform even more genotyping using the Illu-
mina BeadChip arrays.
In the second strategy, genetic variation in the following
cascades and anatomical structures particularly relevant
for FINCAVAS are studied: regulation of blood pressure,
adrenergic signal transduction, cardiac ion channels as
well as pharmacokinetics and pharmacodynamics of
drugs used to treat hypertension and CHD.
In this strategy, DNA samples are genotyped by employ-
ing the 5' nuclease assay and fluorogenic allele-specific
TaqMan MGB probes [32], using the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). The samples are pipetted using an auto-
mated TECAN Freedom EVO-100 pipetting robot (Tecan
Group Ltd, Männedorf, Switzerland). The nucleotide
sequences of the primers and probes used in the polymer-
ase chain reaction (PCR) are deduced from published
sequences deposited in the GenBank and Celera databases
and synthesised by Applied Biosystems. The PCR reac-
tions containing genomic DNA, 1 × Universal PCR Master
Mix, 900 nM of each primer and 200 nM of each probe are
performed in 384-well plates using the standard protocol
in a total volume of 5 µl.
End-point fluorescence is measured and genotype calling
carried out by the allelic discrimination analysis module
after the PCR results in the identification of polymor-
phisms chosen. Negative and positive controls (known
genotypes) and random duplicates are used as quality
control. Genotypes are analysed in the Centre for Labora-
tory Medicine, Department of Clinical Chemistry, Labora-
tory of Atherosclerosis Genetics at Tampere University
Hospital.
Follow-up
The follow-up data consists of information on major car-
diovascular events (hospitalisation due to angina pectoris,
MI or stroke), coronary procedures (angioplasties and
bypass operations) and causes of deaths (Fig. 1). The fol-
low-up data will be gathered at 2, 5 and 10 years. Informa-
tion on clinical events will be collected from the Finnish
National Hospital Discharge Register and data on mortal-
ity from the Causes of Death Register; these sources have
been shown to be reliable [33]. Information on operative
procedures will be received from the Hospital Informa-
tion System of Tampere University Hospital.
Phenotype definitions
The presence of CHD in the patients included in our data-
base can be defined in several ways. First, the existence of
CHD prior to the exercise test is based on patient inter-
views, resting ECG recordings and existing hospital
records. Secondly, the exercise test per se provides infor-
mation on CHD diagnosis; this can be combined with the
pre-test probability of CHD using Bayesian logic. Thirdly,
some 20% of the patients have undergone coronary angi-
ography that unambiguously reveals the status of coro-
nary arteries; different stenosis criteria for CHD can be
established for different purposes. The CHD definition
used in each sub-project depends on the specific aims of
the project.
History of prior MI is based on patient interviews, resting
ECG recordings and hospital records. Data on the exist-
ence of hypertension, valvular diseases, cardiomyopa-
thies, other heart diseases and diabetes (types 1 and 2) is
based on interviews and hospital records. The presence of
abnormal atrio-ventricular conduction, right (RBBB) and
left (LBBB) bundle branch blocks, delta waves, pathologi-
cal Q waves and long QT syndrome are based on resting
ECGs and hospital records.
Data architecture
The material in the FINCAVAS database is woven together
from many data sources (Fig. 1). The patient history data
is based on both patient interview and hospital records;BMC Cardiovascular Disorders 2006, 6:9 http://www.biomedcentral.com/1471-2261/6/9
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the data is recorded with a computer-based form [20].
Data on demographics (i.e., age, sex, weight, height, body
mass index, waist to hip ratio, occupation) and lifestyle
(alcohol consumption, physical exercise at work and lei-
sure time) is collected using the same software before the
exercise test. Furthermore, exposure to classic cardiovascu-
lar risk factors (i.e., smoking, hypertension, diabetes,
occurrence of hyperlipidemia and family history) is cov-
ered extensively.
Cardiovascular symptoms (including the functional
capacity classification developed by the New York Heart
Association, NYHA) and diseases are recorded in detail,
with special emphasis on CHD and prior MIs. All the
medications used by the patient are entered into the data-
base, including the length of possible pause before the
exercise test.
The actual exercise tests generate the majority of the data.
Values for HR, SAP, DAP, breathing frequency, physical
load, perceived exertion level, peak expiratory flow before
and after the exercise as well as oxygen saturation in a fin-
ger tip, if measured, are gathered on the software men-
tioned earlier.
Continuous ECG is recorded at 500 Hz with CardioSoft
exercise ECG system (Version 4.14, GE Healthcare,
Freiburg, Germany) and analysed by Modified CASE soft-
ware (GE Healthcare, Freiburg, Germany). The system rec-
ognises ventricular escape beats, premature ventricular
complexes (PVC), premature supraventricular complexes,
pauses of 1 or 2 missed beats, ventricular bigeminy, ven-
tricular couplets (2 PVCs), ventricular runs (> 2 PVCs),
ventricular tachycardia, atrial fibrillation/flutter, ventricu-
lar fibrillation and asystole. In addition, the following
parameters are assessed and recorded: amplitudes of P, Q,
R, S and T; durations of P, Q, R, S, RP and QT; levels of J-
point and ST-segments at 60 ms; ST integral; ST slope; T
wave alternans; ST-segment depression/heart rate (ST/
HR) index; ST/HR slope; ST/HR hysteresis [34,35] and,
finally, HR recovery and noise level. These parameters are
determined from 14 ECG leads: aVL, I, -aVR, II, aVF, III, V1
to V6, CM5 and V4R. Furthermore, all these parameters
are determined at 14 points in time: before exercise, seven
times during the exercise (start, 2 min, 4 min, 6 min, 8
min, 10 min and maximal load), and six times during the
rest after the exercise (1 min, 2 min, 3 min, 4 min, 5 min
and 6 min). Therefore, more than 3,500 ECG parameters
are determined for each exercise test and stored into a sep-
arate database. However, any other points in time besides
the ones specified here as well as additional parameters
can be analysed as needed based on the continuous digital
ECG recordings.
Raw data on laboratory tests is received from Tampere
University Hospital. This bulk of data covers all the labo-
ratory tests performed on the study patients. Minimum
and maximum values for each test on each patient are
searched using database queries and recorded into the
FINCAVAS database.
The data on operative procedures is collected from the
Hospital Information System of Tampere University Hos-
pital. For each patient, an angiography is linked to an
exercise test if they were a maximum of 6 months apart,
and if no coronary bypass operations or coronary angi-
oplasties are performed between them.
All the coronary angiographies are analysed by the same
dedicated cardiologist (MN). TIMI (thrombolysis in myo-
cardial infarction) flow, diameter and %-stenosis in the
ostial, proximal, middle and distal parts of the left main
(LM), the left anterior descending (LAD), the left circum-
flex (LCX), and the right (RCA) coronary arteries are regis-
tered. Furthermore, the same parameters are assessed for
major branches: the diagonal branches I and II as well as
the first septal branch of the LAD; the left obtuse marginal
I and II as well as posterior descending branches of the
LCX; posterior descending, right ventricular and posterior
left ventricular branches of the RCA; and, finally, the left
intermediate marginal branch. The stenoses are graded
into seven categories: 0%, <50%, 50–74%, 75–89%, 90–
98%, 99% and 100%.
With the exception of ECG parameters, the data depicted
above is combined into a single SPSS file (release 12.0.1
for Windows, SPSS Inc, Chicago, Illinois, USA). The file
comprises of 510 variables. Due to the enormous amount
of ECG data, the ECG parameters are stored in separate
files and will be added to the SPSS file based on the
requirements of each subproject.
Data validation
Laboratory and ECG data are entered into source data-
bases or data files electronically and automatically. The
other sources necessitate manual input. However, trans-
ferring the data from separate databases to the FINCAVAS
database is done electronically using database tables and
queries. Adequate cross-checks are done to ensure the
accuracy of the data. Furthermore, data is validated by
checking missing data and the plausibility of the ranges of
values, as well as by inspecting the consistency of related
data fields. Errors identified by these procedures result in
checking the raw data when possible or eliminating the
incorrect piece of data.
Discussion
FINCAVAS is aimed at characterising individuals with a
high risk of cardiovascular diseases and death. By the endBMC Cardiovascular Disorders 2006, 6:9 http://www.biomedcentral.com/1471-2261/6/9
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of 2004, data had been gathered on more than 2,200
patients. The recruitment period will continue until the
end of 2007, and the final number of patients is estimated
to reach 5,000. All of the participants will go through
detailed interviews and a clinical exercise test. Moreover,
approximately 20% of the patients will be examined with
coronary angiography, and 5–10% will perform another
exercise test during the study period. The high number of
exercise tests combined with other related data is one of
the particular strengths of this study. To our knowledge,
this is the first large-scale database with digitally recorded
high resolution ECG data covering the entire duration of
the exercise test.
Traditional ECG parameters for CHD diagnosis during
exercise test – such as the amount and type of depression
of the ST segment as well as T wave changes – are reason-
ably accurate in patients with an intermediate pre-test
likelihood for having disease [36,37]. However, the test
lacks sensitivity and specificity for many patient groups,
particularly among women [38]. A central objective of
FINCAVAS is to enhance the accuracy of exercise ECG in
diagnosing CHD by combining some of the existing
markers and by creating completely new algorithms. The
digital high-resolution exercise ECG of the patients under-
going a coronary angiography is a valuable and funda-
mental resource for this purpose.
Several studies have demonstrated exercise capacity as an
independent predictor of cardiac events and mortality in
healthy persons and those with cardiac diseases [2,7-
9,39]. The HR profile during exercise and recovery is a pre-
dictor of death [5,6,10]. Furthermore, the changes in
blood pressure during and after exercise have been shown
to predict cardiovascular events and mortality [4,40].
However, the importance of various combinations of the
predictive parameters is poorly known. When it comes to
ECG parameters, ST depression [2] and ST/HR analysis [3]
during exercise have been connected to survival, but no
studies thus far have revealed whether the values of and
changes in T wave alternans, ST/HR hysteresis [34,35], HR
variability and many other ECG parameters during exer-
cise are linked with mortality. Our research team has
made extensive and persistent efforts in studying the
sophisticated CHD diagnostics based on ECG parameters
and ECG leads [34,41-44]. The present continuous ECG at
500 Hz during the entire exercise test provides a solid
foundation for testing the relevance of both existing prog-
nostic parameters and those developed during the project.
The importance of classical risk factors for atherosclerosis
has been evaluated in detail. In recent years, many genetic
polymorphisms have been associated with atherosclerosis
[45,46]. However, the majority of these new risk factors
provide limited contribution to the total risk of cardiovas-
cular morbidity and mortality. Therefore, defining and
measuring specific and precise phenotypes is of crucial
value when the quantitative importance of these risk fac-
tors and markers are assessed.
Some of the phenotype data included in FINCAVAS, such
as angiographic findings and ECG parameters, can be con-
sidered particularly accurate. Blood pressure and breath-
ing parameters during the exercise test are also accurate,
while medical history may constitute the data most vul-
nerable to imprecision. Knowledge of the pharmaceuti-
cals used and prior diseases are collected with care, but the
process inherently bears some level of uncertainty. Many
middle-aged and elderly individuals are suffering from
considerable atherosclerosis and CHD although they may
remain undiagnosed. Even MI, the most serious complica-
tion of CHD, is often silent and diagnosed only when a
routine ECG is recorded. The level of uncertainty for each
phenotype needs to be taken into account when the
results of analyses and classifications using these parame-
ters are interpreted.
Many polymorphisms are most likely not disease-causing
genes, but rather risk modifiers, and might thus also influ-
ence the progression of cardiovascular diseases. Although
certain polymorphisms do not induce marked effects on
cardiovascular parameters, they may still have linkage
effects with some functionally more important polymor-
phisms. In the course of FINCAVAS, the independent and
combined effects of many genotypic variations on cardio-
vascular morbidity and mortality will be assessed prospec-
tively with a long-term follow-up. The purpose of this
strategy is not only to study the effects of polymorphisms
on known risk factors, but also to find new mechanisms
and factors contributing to the aetiology of cardiovascular
diseases directly in the arterial wall. To achieve this goal,
we will exploit and use high throughput techniques for
expression analysis and genotyping to find genes affecting
the expression, synthesis and function of proteins associ-
ated with cell signal transduction, regulation of inflam-
mation, apoptosis and lipid metabolism directly in the
cells of the arterial wall. Better understanding of the func-
tion of the genes in these cells during the progression of
cardiovascular disease could serve as a new tool in both
research and therapeutic applications.
FINCAVAS is subject to certain limitations. We include all
patients scheduled for a clinical exercise test at a university
setting, which is both a strength and a weakness of the
study. The present study population consists of patients
with a wide spectrum of ages, life styles, histories and sta-
tus of cardiac diseases. It is probable that the importance
of many genotypes, responses to exercise and ECG mark-
ers vary from one patient group to another. Therefore, the
study enables the assessment of risks for many patientBMC Cardiovascular Disorders 2006, 6:9 http://www.biomedcentral.com/1471-2261/6/9
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groups, but, on the other hand, these groups need to be
adequately recognised before analyses. In some cases, the
subgroups may still be relatively small in spite of the high
total number of patients.
In conclusion, FINCAVAS is compiling an extensive set of
data on patient history, genetic variation, cardiovascular
parameters and ECG markers prior to, during and after an
exercise test. Furthermore, approximately 20% of the
patients are being examined with coronary angiography.
As the follow-up progresses, this data will enable us to
estimate the importance of different diagnostic and prog-
nostic markers for many distinct patient groups.
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